1 completed, 1 recruiting. 2 Phase 1, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 2 | Completed 1, Recruiting 1 |
| Phase 2 | 1 | Completed 1 |
Follow Systemic Amyloidosis: new trials by email Literature Review of Systemic Amyloidosis trials Research Report on Systemic Amyloidosis
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Phase 1 Study of 99mTc-p5+14 in Healthy Volunteers and Patients With AL or ATTR Systemic Amyloidosis 99mTc-p5+14 is an amyloid reactive peptide labeled with technetium-99m., 99mTc-Pyrophosphate - Systemic Amyloidosis | Phase 1 | Recruiting | University of Tennessee Graduate School of Medicine | 31 | 2023-09-18 | 2026-07-24 |
| 124I-p5+14 Injection Safety in Subjects With Systemic Amyloidosis 124I-p5+14 Injection - Systemic Amyloidosis | Phase 1 / Phase 2 | Completed | University of Tennessee Graduate School of Medicine | 57 | 2018-10-01 | 2022-03-25 |
Amyloidosis (2) · Immunoglobulin Light-chain Amyloidosis (2)
Immune System Diseases (2) · Immunoproliferative Disorders (2) · Lymphoproliferative Disorders (2) · Metabolic Diseases (2) · Neoplasms (2) · Neoplasms by Histologic Type (2) · Neoplasms, Plasma Cell (2) · Nutritional and Metabolic Diseases (2) · Paraproteinemias (2) · Proteostasis Deficiencies (2)
Technetium (1) · Technetium Tc 99m Pyrophosphate (1)
University of Tennessee Graduate School of Medicine (2)
United States (2)
Jonathan S Wall, PhD (1) · Jonathan Wall, Ph.D. (1)